

Molecular Tumor Board

Molecular Tumor Board - 6/5/2025

Online

June 5, 2025 – 12:00 PM

Learning Objectives

Upon completion of this session, learners should be able to:

- 1 Interpret a patient's molecular profile and identify therapeutically-actionable driver mutations and incidental germline variants requiring further assessment by geneticists.
- 2 Identify the resources available to facilitate a precision medicine strategy.
- 3 Evaluate patient outcomes through the collaborative review and analysis of case reports and broad analyses during tumor board meetings.

Target Audience

Specialties – Anatomy-Clinical Pathology, Basic Science, Oncology, Radiation Oncology, Radiology
Professions – Physician, Non-Physician, Advanced Practice Nurse, Fellow/Resident, Genetic Counselor, Nurse, Pharmacist, Physician Assistant, Scientist / Researcher

Accreditation

The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of California San Diego School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society.

Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 Credits*[™] issued by organizations accredited by the ACCME. For relicensure, the California Board of Registered Nursing accepts *AMA PRA Category 1 Credits*[™].

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement

All relevant financial relationships and the nature of those relationships are noted below. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
---------------------------	--------------------------------------	--

Suzanna Lee, MPH	Activity Coordinator	Nothing to disclose - 02/04/2025
Lisa Madlensky, PhD, CGC	Faculty, Planning Committee Member	Advisor-VieCure - 09/26/2024
Angelique Richardson, MD, PhD	Planning Committee Member	
Sandip Patel, MD	Co-Director	Advisor-Amgen, AstraZeneca, Bristo-Myers Squibb, Certis, Eli Lilly, Jazz, Advisor-Roche Genentech Advisor-Caris, Guardant, Illumina, Merck, Nuvalent, Pfizer, Tempus - 05/21/2025
Kay T. Yeung, MD, PhD	Faculty, Planning Committee Member	Grant or research support-Pfizer Grant or research support-Biofluidica (Relationship has ended) Grant or research support-Dantari Grant or research support-Gilead Sciences, Inc. Grant or research support-Regeneron Pharmaceuticals, Inc. Grant or research support-Seattle Genetics, Inc. Grant or research support-Jazz Pharmaceuticals, Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.-Elsevier Grant or research support-Treadwell Therapeutics - 06/09/2024
Wei Song, MD, PhD	Planning Committee Member	Employment-Guardant Health (Relationship has ended) Advisor-AstraZeneca (Any division) (Relationship has ended) - 03/03/2025
Shumei Kato, NA	Course Director, Faculty	

Acknowledgment of Commercial Support

This session has received no commercial support.